Advertisement

U.S. markets open in 6 hours 12 minutes

S&P Futures
3,925.25
+21.50(+0.55%)
Dow Futures
31,585.00
+164.00(+0.52%)
Nasdaq Futures
12,115.25
+74.75(+0.62%)
Russell 2000 Futures
1,783.10
+13.30(+0.75%)
Crude Oil
111.45
+1.88(+1.72%)
Gold
1,829.10
+4.30(+0.24%)

Advertisement

Vir Biotechnology, Inc. (VIR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

26.65

+1.81

(+7.29%)

At close: 04:00PM EDT

26.65

0.00

(0.00%)

After hours:

07:34PM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Momentum

View all chart patterns

Performance Outlook

Previous Close	24.84
Open	25.08
Bid	0.00 x 1300
Ask	0.00 x 1300
Day's Range	24.81 - 26.89
52 Week Range	18.21 - 58.00
Volume	1,429,147
Avg. Volume	1,632,670

Market Cap	3.528B
Beta (5Y Monthly)	-0.58
PE Ratio (TTM)	2.96
EPS (TTM)	8.99
Earnings Date	Aug 03, 2022 - Aug 08, 2022
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	52.71

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Undervalued

31% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for VIR

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Vir Biotechnology, Inc.
VIR: Lowering target price to $20.00VIR BIOTECHNOLOGY INC has an Investment Rating of SELL; a target price of $20.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.
Rating
Fair Value
Economic Moat
6 days agoArgus Research

All

Zacks
Immatics (IMTX) Stock Jumps 5.2%: Will It Continue to Soar?
Immatics (IMTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
GlobeNewswire
Vir Biotechnology Announces New Clinical Data From its Broad Hepatitis B Program
– Results from ongoing trials of VIR-2218 and VIR-3434 presented at the International Liver Congress™ (ILC) 2022 demonstrate durable reductions in hepatitis B surface antigen with no safety signals – – Company expects to dose first patient in Part B of the Phase 2 MARCH trial by the end of June – SAN FRANCISCO, June 25, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new data from its robust hepatitis B virus (HBV) clinical trial program, including results from an
- Eliem Therapeutics Announces Last Patient Completed Dosing in Phase 2a Study of ETX-810 in Patients with Lumbosacral Radicular Pain (LSRP)
  GlobeNewswire
- Adial Pharmaceuticals Announces Database Lock for the ONWARD™ Phase 3 Clinical Trial
  GlobeNewswire
Motley Fool
Buy the Dip on These 3 Healthcare Stocks
With the S&P 500 down over 23% year to date, investors looking for safety are eyeing the healthcare industry. Taylor Carmichael (Vir Biotechnology): Vir Bio is down about 45% in 2022, but it is one of my highest-confidence positions in healthcare right now. When the Food and Drug Administration gave Vir -- and its partner, GlaxoSmithKline -- an Emergency Use Authorization (EUA) for its COVID-19 treatment sotrovimab (trademark Xevudy), demand for the drug skyrocketed.